Nurix CLO sells shares, exercises options

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock.

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock. She sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan, with sale prices ranging from $16.35 to $17.10. In a related move, she exercised employee stock options covering 3,422 shares at an exercise price of $1.86 per share, converting them into common stock. Following these transactions, she directly holds 13,579 shares of common stock and 5,221 employee stock options.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 8,148 shs ($135K)

Approx. gross sale proceeds $135K

Approx. exercise cost $6K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	3,422	$0.00	$0.00
Exercise	Common Stock	3,422	$1.86	$6K
Sale	Common Stock	8,148	$16.5995	$135K

Holdings After Transaction: Employee Stock Option (right to buy) — 5,221 contracts (Direct); Common Stock — 13,579 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.35 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Key Figures

Shares sold: 8,148 shares Weighted average sale price: $16.5995 per share Options exercised: 3,422 shares +3 more

6 metrics

Shares sold 8,148 shares Open-market sale of common stock

Weighted average sale price $16.5995 per share Common stock sale price; range $16.35–$17.10

Options exercised 3,422 shares Employee stock options converted into common stock

Option exercise price $1.86 per share Exercise or conversion price for employee stock options

Common shares after transactions 13,579 shares Direct common stock holdings following transactions

Options remaining after exercise 5,221 options Employee stock options outstanding after exercise

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sale price

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy) transaction for 3,422.0000 shares at a conversion or exercise price of 1.8600."

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $16.35 and the highest price at which shares were sold was $17.10."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Nurix Therapeutics (NRIX) disclose for Christine Ring?

Nurix Therapeutics disclosed that Chief Legal Officer Christine Ring sold 8,148 common shares and exercised options for 3,422 shares. These transactions involved open-market sales and an employee stock option exercise reported in a recent Form 4 filing.

At what prices did Christine Ring sell Nurix Therapeutics (NRIX) shares?

Christine Ring’s Form 4 reports a weighted average sale price of $16.5995 per share. Individual sale prices ranged from $16.35 to $17.10, reflecting multiple trade executions within that price band during the reported transaction.

How many Nurix Therapeutics (NRIX) shares did Christine Ring sell and acquire?

Christine Ring sold 8,148 shares of Nurix Therapeutics common stock and acquired 3,422 shares through exercising employee stock options. The transactions combine an open-market sale with the conversion of stock options into additional common shares.

What is Christine Ring’s Nurix Therapeutics (NRIX) stake after the reported transactions?

After the reported transactions, Christine Ring directly holds 13,579 shares of Nurix Therapeutics common stock and 5,221 employee stock options. These figures come from the post-transaction ownership amounts listed in the Form 4 filing.

Were the Nurix Therapeutics (NRIX) insider sales pre-planned under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that the sale of Nurix Therapeutics shares by Christine Ring was effected pursuant to a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-arranged rather than discretionary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 07:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		M(1)		3,422	A	$1.86	21,727	D
Common Stock	06/02/2026		S(1)		8,148	D	$16.5995(2)	13,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	06/02/2026		M(1)			3,422	(3)	09/30/2029	Common Stock	3,422	$0	5,221	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $16.35 and the highest price at which shares were sold was $17.10. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)